Tugce Duran, Ercan Kurar, Zeliha Tuncer, Canan Eroglu Gunes

Apoptotic effect of Belinostat (PXD101) on MCF-7 cancercells

Aim: Breast cancer continues to be the most common type of cancer among women. Recent development in epigenomics hashighlighted key mechanisms in which epigenetic regulation contributes to cancer treatment. Epigenetic modulating drugs promises novel approaches targeting cancer treatment. Belinostat is a histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2014 for the T-cell lymphoma. This study aimed to investigate the apoptotic effects of Belinostat on MCF-7 cells. Materials and Methods: For this purpose, The IC50 value of Belinostat was determined by XTT assay and the apoptotic effect ofBelinostat on MCF-7 cells was evaluated. Expression of apoptosis-related genes including Caspase 3 (CASP3), CASP9, apoptotic protease activating factor-1 (APAF-1) and tumor protein P53 (P53) were evaluated by quantitative Real-Time PCR.Results: The IC50 dose of Belinostat was determined as 5 μM for 48 h. The results of study showed that Belinostat administrationdecreased the number of cancer cells in the MCF-7 cell population and down regulated the gene expression of apoptosis-related genes.Conclusion: Results indicated that Belinostat, can be considered as an option in the treatment of breast cancer. It is considered thatit would be more beneficial to perform more sophisticated in vivo and in vitro studies about apoptotic effect of Belinostat.

PDF

___

1. Hausman DM. What is cancer? Perspect Biol Med 2019;778-84.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics. CA
Cancer J Clin 2016;66:7-30. 3. https://hsgm.saglik.gov.tr/tr/kanser-istatistikleri
4. Sun YS, Zhao Z, Yang ZN, et al. Risk factors
and preventions of breast cancer. Int J Biol Sci
2017;13:1387-97.
5. Park JW, Han JW. Targeting epigenetics for cancer
therapy. Arch Pharm Res 2019;42:159-170.
6. Kejík Z, Jakubek M, Kaplánek R, et al. Epigenetic
agents in combined anticancer therapy. Future Med
Chem 2018;10:1113-30.
7. Olzscha H, Bekheet ME, Sheikh S, et al. HDAC inhibitors.
Histone Deacetylases. Human a Press, New York, NY.
2016;1436:281-303.
8. Buchwald M, Krämer OH, Heinzel T. HDACi-targets
beyond chromatin. Cancer Lett 2009;280:160-7.
9. Yoon S, Eom GH. HDAC and HDAC inhibitor: from
cancer to cardiovascular diseases. Chonnam Med J 2016; 52:1-11.
10. Ong PS, Wang L, Chia DM, et al. A novel combinatorial strategy using Seliciclib® and Belinostat® for eradication of non-small cell lung cancer via
apoptosis induction and BID activation. Cancer Lett
2016;381:49-57.
11. Campbell P, Thomas CM. Belinostat for the treatment
of relapsed or refractory peripheral T-cell lymphoma.
J Oncol Pharm Pract 2017;23:143-7.
12. Ito Y, Makita S, Tobinai K. Development of new agents
for peripheral T-cell lymphoma. Expert Opin Biol Ther
2019;19:197-209.
13. Singh AK, Bishayee A, Pandey AK. Targeting histone
deacetylases with natural and synthetic agents: An
emerging anticancer strategy. Nutrients 2018;10:731.
14. Elmore S. Apoptosis: a review of programmed cell
death. Toxicol Pathol 2007;35:495-516.
15. Fan TJ, Han LH, Cong RS et al. Caspase family
proteases and apoptosis. Acta Bioc Bioph Sin
2005;37:719-27.
16. Shawgo ME, Shelton SN, Robertson JD. Caspase-
mediated BAK activation and cytochrome C release
during intrinsic apoptotic cell death in Jurkat cells. J
Biol Chem 2008;283:35532-38.
17. Fulda S, Debatin KM. Extrinsic versus intrinsic
apoptosis pathways in anticancer chemotherapy.
Oncogene 2006;25:4798-811.
18. World Health Organization. https://www.who.int/ health-topics/cancer#tab=tab_1
19. Dawson MA, Kouzarides T. Cancer epigenetics: from
mechanism to therapy. Cell. 2012;150:12-27.
20. Prachayasittikul V, Prathipati P, Pratiwi R, et al.
Exploring the epigenetic drug discovery landscape.
Expert Opin Drug Discov 2017;12:345-62.
21. Dejligbjerg M, Grauslund M, Christensen IJ, et al.
Identification of predictive biomarkers for the histone
deacetylase inhibitor belinostat in a panel of human
cancer cell lines. Cancer Biomark 2008;4:101-9.
22. Androutsopoulos, VP, Spandidos DA. Antiproliferative
effects of TSA, PXD 101 and MS 275 in A2780 and
MCF7 cells: Acetylated histone H4 and acetylated
tubulin as markers for HDACi potency and selectivity.
Oncol Rep 2017;38:3412-8.
23. He J, Wang S, Liu X et al. Synthesis and biological
evaluation of HDAC inhibitors with a novel Zinc
Binding Group. Front Chem 2020;8:256.
24. Lu P, Gu Y, Li L, et al. Belinostat suppresses cell
proliferation by inactivating Wnt/β-catenin pathway
and promotes apoptosis through regulating PKC
pathway in breast cancer. Artif Cells Nanomed
Biotechnol 2019;47:3955-60.
25. Eckschlager T, Plch J, Stiborova M, et al. Histone deacetylase inhibitors as anticancer drugs. Int J Mol
Sci 2017;18:1414
26. Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency,
differentiation, and reprogramming. Stem Cells Int
2012;2012:184154.
27. Lee HA, Chu KB, Moon EK, et al. Sensitization to
oxidative stress and G2/M cell cycle arrest by histone
deacetylase inhibition in hepatocellular carcinoma
cells. Free Radical Bio Med 2020;147:129-38.
28. Yang F, Zhao N, Song J, et al. Design, synthesis
and biological evaluation of novel coumarin-based
hydroxamate derivatives as histone deacetylase
(HDAC) inhibitors with antitumor activities. Molecules
2019;24,14: 2569.
29. Pathil A, Armeanu S, Venturelli S, et al. HDAC inhibitor
treatment of hepatoma cells induces both TRAIL-
independent apoptosis and restoration of sensitivity
to TRAIL. Hepatology 2006;43:425-34.
30. Herold C, Ganslmayer M, Ocker M, et al. The
histone-deacetylase inhibitor Trichostatin A blocks
proliferation and triggers apoptotic programs in
hepatoma cells. J Hepato 2002;36:233-40.
31. Chiba T, Yokosuka O, Fukai K, et al. Cell growth
inhibition and gene expression induced by the histone
deacetylase inhibitor, trichostatin A, on human
hepatoma cells. Oncology 2004;66:481-91.
32. Liu S, Bishop WR, Liu M. Differential effects of cell
cycle regulatory protein p21WAF1/Cip1 on apoptosis
and sensitivity to cancer chemotherapy. Drug Resist
Update 2003;6:183-95.